Related Experiment Video
Updated: Aug 9, 2026

08:16
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
Myasthenia gravis masquerading as post-poliomyelitis syndrome
1Rehabilitation Medicine Unit, Astley Ainslie Hospital, Edinburgh, UK. rajiv.singh@lpct.scot.nhs.uk
Journal of Rehabilitation Medicine
|March 21, 2006
Summary
Post-polio syndrome can mimic other neurological conditions like myasthenia gravis. Reconsidering diagnoses is crucial when new symptoms emerge in patients with prior polio.
Area of Science:
- Neurology
- Infectious Diseases
Background:
- Poliomyelitis is a debilitating infectious disease with potential long-term neurological sequelae.
- Post-polio syndrome (PPS) is characterized by new-onset neuromuscular symptoms years after the initial poliovirus infection.
Observation:
- A 79-year-old male with a history of bulbar poliomyelitis presented with progressive dysphagia.
- The patient was initially diagnosed with post-polio syndrome, experiencing worsening swallowing difficulties and aspiration pneumonia over two years.
- New symptoms of fatigue and facial weakness led to a subsequent diagnosis of myasthenia gravis.
Findings:
- The diagnostic criteria for post-polio syndrome necessitate the exclusion of other neurological disorders.
- Myasthenia gravis, a distinct neuromuscular condition, shares some overlapping symptoms with PPS, such as muscle weakness and fatigue.
- This case highlights the importance of differential diagnosis in complex neurological presentations.
Implications:
- Clinicians should maintain a high index of suspicion for alternative diagnoses when patients with established conditions like PPS develop new or worsening symptoms.
- Accurate and timely diagnosis is critical for effective management and to prevent complications such as aspiration pneumonia.
- This case underscores the need for ongoing reassessment of diagnoses in patients presenting with evolving neurological deficits.
Related Concept Videos
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...